WEBULL
News
DRMAW
0.0215
+10.82%
0.0021
Weekly Report: what happened at DRMAW last week (1124-1128)?
Weekly Report · 6d ago
DERMATA THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $100 MLN - SEC FILING
Reuters · 11/24 16:22
Weekly Report: what happened at DRMAW last week (1117-1121)?
Weekly Report · 11/24 09:06
DERMATA THERAPEUTICS : VILLANI WILL NOT BE ENTITLED TO RECEIVE ANY FURTHER MILESTONES OR OTHER PAYMENTS DUE AFTER TERMINATION DATE
Reuters · 11/18 11:02
DERMATA THERAPEUTICS INC - ON NOV 17, TERMINATES LICENSE AGREEMENT WITH VILLANI DATED MARCH 31, 2017 - SEC FILING
Reuters · 11/18 11:02
Weekly Report: what happened at DRMAW last week (1110-1114)?
Weekly Report · 11/17 09:06
Dermata Therapeutics Q3 net loss narrows as R&D expenses fall
Reuters · 11/14 21:20
DERMATA THERAPEUTICS INC - TO LAUNCH FIRST OTC ACNE KIT MID-2026 - SEC FILING
Reuters · 11/14 21:18
Dermata Therapeutics Announces Strategic Shift to Over-the-Counter Dermatology Market, Plans Mid-2026 Launch of Once-Weekly Acne Kit Featuring Spongilla Technology
Reuters · 11/14 21:10
Weekly Report: what happened at DRMAW last week (1103-1107)?
Weekly Report · 11/10 09:06
Weekly Report: what happened at DRMAW last week (1027-1031)?
Weekly Report · 11/03 09:06
Weekly Report: what happened at DRMAW last week (1020-1024)?
Weekly Report · 10/27 09:06
Weekly Report: what happened at DRMAW last week (1013-1017)?
Weekly Report · 10/20 09:06
Weekly Report: what happened at DRMAW last week (1006-1010)?
Weekly Report · 10/13 09:06
Weekly Report: what happened at DRMAW last week (0929-1003)?
Weekly Report · 10/06 09:06
Dermata Therapeutics Announces Australian Patent Office Accept Patent Application For Spongilla Technology Combination As Method For Treating Acne
Benzinga · 10/02 12:02
Dermata Therapeutics’ Spongilla Acne Treatment Patent Application Accepted by Australian Patent Office
Reuters · 10/02 12:00
Weekly Report: what happened at DRMAW last week (0922-0926)?
Weekly Report · 09/29 09:06
Weekly Report: what happened at DRMAW last week (0915-0919)?
Weekly Report · 09/22 09:06
Dermata Therapeutics Announces Presentation of Phase 3 Clinical Trial Results for XYNGARI™ at EADV Congress 2025
Reuters · 09/17 05:00
More
Webull provides a variety of real-time DRMAW stock news. You can receive the latest news about Dermata Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About DRMAW
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, DMT310, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 50 million patients. Its second product candidate utilizing its Spongilla technology is DMT410, its combination treatment. DMT410 is intended to consist of one treatment of its proprietary sponge powder followed by one topical application of botulinum toxin for delivery into the dermis.